Specialty medicines • Bangladesh

Cabozanix 20 MG & 60 MG (Cabozantinib)

Product Name : Cabozanix
Generic Name : Cabozantinib
Formulation : Film-Coated Tablet
Available Pack Size : 30/90 Tablets per pot
Available Strengths : 20 mg, 60 mg
Manufacturer : Beacon Pharmaceuticals PLC
Country Of Origin : Bangladesh

Confirm your order

Speak with our team about your prescribed strength, pack size, price and delivery.
Use medicines only as prescribed by your clinician.

Description

 

Cabozanix 20 MG & 60 MG (Cabozantinib) is a highly potent, orally bioavailable, broad-spectrum multi-kinase inhibitor formulated as a film-coated tablet that simultaneously targets vascular endothelial growth factor receptors VEGFR-1, VEGFR-2, and VEGFR-3, the hepatocyte growth factor receptor MET (c-MET), the receptor tyrosine kinase AXL, the rearranged during transfection proto-oncogene receptor RET, and multiple additional oncogenic kinases including KIT, TRKB, FLT-3, and TIE-2 a mechanistically differentiated precision oncology agent whose simultaneous multi-kinase blockade addresses both the primary VEGF-driven tumor angiogenesis pathway and the most clinically validated resistance escape mechanisms in a single orally administered film-coated tablet; cabozantinib’s concurrent inhibition of VEGFR, MET, and AXL is its defining pharmacological advantage over all first-generation and second-generation VEGFR-selective TKIs tumors treated with VEGFR-only inhibitors (sunitinib, sorafenib, axitinib) adaptively upregulate MET and AXL signaling as resistance escape routes, allowing continued tumor cell proliferation and survival independently of VEGFR activity; cabozantinib closes these escape routes simultaneously with VEGFR blockade, while its RET kinase inhibition provides direct oncogenic driver activity suppression in RET-activated thyroid cancers; the film-coated tablet formulation of Cabozanix delivers cabozantinib with the full established bioavailability profile of the reference tablet formulation, enabling complete dose management from two tablet strengths, supplied as a film-coated tablet in strengths of 20 mg and 60 mg, available in 90 and 30 tablets per pot, and manufactured by Beacon Pharmaceuticals PLC, Bangladesh.

 

Cabozantinib, the active pharmaceutical ingredient of Cabozanix, is a multi-kinase inhibitor with four FDA-approved oncology indications in the film-coated tablet formulation establishing cabozantinib as a standard-of-care agent for adult patients with advanced renal cell carcinoma (RCC), including as first-line treatment in combination with nivolumab (anti-PD-1 immune checkpoint inhibitor) and as monotherapy at any line of RCC therapy; for adult patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib; for adult and pediatric patients 12 years of age and older with locally advanced or metastatic differentiated thyroid cancer (DTC) that has progressed following prior VEGFR-targeted therapy and who are radioactive iodine-refractory or ineligible; and for adult and pediatric patients 12 years of age and older with previously treated pancreatic and extra-pancreatic neuroendocrine tumors (NET) as of the March 2025 FDA approval representing the broadest multi-indication tablet-formulation VEGFR-MET-AXL-RET kinase inhibitor in oncology.

 

The recommended dose of Cabozanix (Cabozantinib) is 60 mg orally once daily on an empty stomach (at least 1 hour before or at least 2 hours after eating) as monotherapy for advanced RCC, previously treated HCC, previously treated DTC, and previously treated NET, and 40 mg orally once daily on an empty stomach in combination with nivolumab 240 mg every 2 weeks or 480 mg every 4 weeks for first-line advanced RCC; the 60 mg once-daily monotherapy dose is administered as one 60 mg tablet the most patient-friendly single-tablet-per-day dosing regimen for a multi-kinase inhibitor; the 20 mg tablet enables the 40 mg combination dose (two 20 mg tablets), all 20 mg dose reductions from 60 mg to 40 mg and from 40 mg to 20 mg, and pediatric weight-based dosing adjustments; cabozantinib tablets must be taken on an empty stomach and must not be taken with grapefruit or grapefruit juice (significant CYP3A4/5 inhibition); strong CYP3A4 inhibitors require a 20 mg dose reduction; strong CYP3A4 inducers (rifampin, phenytoin, carbamazepine, St. John’s Wort) require a 20 mg dose increase if tolerated; cabozantinib must be withheld for at least 3 weeks prior to elective surgery due to wound-healing impairment risk; do not administer to patients with active or recent serious hemorrhage.

 

The pivotal Phase III CheckMate 9ER trial (NCT03141177), enrolling 651 patients with previously untreated advanced RCC, demonstrated that nivolumab plus cabozantinib delivered a confirmed ORR of 55.7% versus 27.7% with sunitinib more than doubling objective response rate and doubled median progression-free survival (HR 0.51; 95% CI 0.41–0.64; p<0.0001) at 4-year minimum follow-up, with a statistically significant overall survival benefit (HR 0.70; 95% CI 0.55–0.90), establishing nivolumab plus cabozantinib as the most widely prescribed TKI plus immunotherapy combination for first-line advanced RCC as of 2025. The pivotal Phase III CELESTIAL trial (NCT01908426) demonstrated statistically significant improvement in median overall survival of 10.2 months with cabozantinib versus 8.0 months with placebo (HR 0.76; 95% CI 0.63–0.92; p=0.0049) in previously sorafenib-treated advanced HCC, establishing cabozantinib as a validated second-line or later-line standard of care for advanced liver cancer.

 

Important: The most clinically significant adverse reactions of cabozantinib film-coated tablets are hemorrhage (including fatal events), gastrointestinal perforations and fistulas, arterial and venous thrombotic events, hypertension (including hypertensive crisis), diarrhea, palmar-plantar erythrodysesthesia (PPE/hand-foot syndrome), hepatotoxicity, osteonecrosis of the jaw, Reversible Posterior Leukoencephalopathy Syndrome (RPLS), thyroid dysfunction, hypocalcemia, wound healing complications, and embryo-fetal toxicity.

 

Severe and fatal hemorrhagic events have been reported; do not administer to patients with recent serious hemorrhage; permanently discontinue for Grade 3 or 4 hemorrhage. Cabozantinib must be withheld for at least 3 weeks before any elective surgical procedure and resumed no sooner than 2 weeks after adequate wound healing. Monitor hepatic function (ALT, AST, bilirubin) before and periodically during treatment; withhold or permanently discontinue for severe hepatotoxicity.

 

Monitor calcium before initiating and during treatment; withhold for clinically significant hypocalcemia and resume at a reduced dose when corrected. Monitor blood pressure before initiating and throughout treatment; permanently discontinue for hypertensive crisis or severe uncontrolled hypertension. Cabozantinib can cause fetal harm; females of reproductive potential must use effective contraception during treatment and for 4 months after the last dose; males must use condoms during treatment and for 4 months after the last dose; breastfeeding is not recommended during treatment and for 4 months after the last dose.

 

Do not substitute Cabozanix 20 MG & 60 MG Cabozantinib tablets for sunitinib, sorafenib, lenvatinib, axitinib, or other targeted kinase inhibitors, or substitute between cabozantinib tablet and capsule formulations, without confirmed indication-specific prescribing and clinical benefit-risk assessment by the treating oncologist. Searching for Cabozanix 20 MG & 60 MG Cabozantinib? Mediaid Pharmacy lists this product across its oncology medicines, kidney cancer medicines, liver cancer medicines, thyroid cancer medicines, and Beacon Pharmaceuticals medicines portfolios and ships it worldwide.

Basic Product Information of Cabozanix 20 MG & 60 MG (Cabozantinib)

Brand Name Cabozanix manufactured and marketed by Beacon Pharmaceuticals PLC, Bangladesh; cabozantinib is also marketed internationally as Cabometyx® film-coated tablets (20 mg, 40 mg, 60 mg) by Exelixis, Inc. (the original innovator company) in the United States Cabometyx received FDA approval for previously treated advanced RCC on April 25, 2016 (60 mg tablets), for previously treated advanced HCC on January 14, 2019, for first-line advanced RCC with nivolumab on January 22, 2021 (40 mg), for previously treated DTC on September 17, 2021, and for previously treated NET in March 2025; Cabozanix by Beacon Pharmaceuticals PLC is a branded generic formulation of cabozantinib film-coated tablets available in 20 mg and 60 mg strengths, manufactured in Bangladesh and supplied through authorized international pharmaceutical distribution channels, providing accessible cabozantinib tablet therapy across kidney cancer, liver cancer, and thyroid cancer indications globally; the 20 mg and 60 mg tablet strengths of Cabozanix cover the full clinically recommended dosing range for all four Cabometyx-equivalent tablet-formulation indications without requiring a 40 mg intermediate-strength tablet
Product Name Cabozanix (branded cabozantinib film-coated tablet, 20 mg and 60 mg per tablet, 90 and 30 tablets per pot, by Beacon Pharmaceuticals PLC, Bangladesh)
Generic Name Cabozantinib (INN; a highly potent, orally bioavailable broad-spectrum multi-kinase inhibitor that simultaneously inhibits VEGFR-1, VEGFR-2, VEGFR-3, MET (c-MET/hepatocyte growth factor receptor), AXL, RET, and additional kinases including KIT, TRKB, FLT-3, and TIE-2; cabozantinib achieves sub-nanomolar to low-nanomolar IC50 values against VEGFR-2 (0.035 nM), MET (1.3 nM), AXL (7 nM), and RET (5.2 nM), establishing simultaneous high-potency inhibition of four distinct oncogenic signaling axes at pharmacologically achievable steady-state plasma concentrations; cabozantinib’s simultaneous VEGFR + MET + AXL + RET inhibition mechanistically distinguishes it from all VEGFR-selective TKIs (sunitinib, sorafenib, axitinib, pazopanib) which inhibit VEGFR kinases but lack meaningful MET and AXL inhibitory activity MET and AXL are well-established primary resistance escape mechanisms activated in response to VEGFR blockade, allowing tumor cell survival independently of the VEGFR pathway; by inhibiting these escape routes simultaneously, cabozantinib addresses both primary tumor angiogenesis and acquired VEGFR-TKI resistance within a single molecule; cabozantinib’s RET kinase inhibition provides oncogenic driver suppression in RET-mutant or RET-rearranged thyroid cancers including differentiated thyroid cancer (DTC) post-VEGFR therapy; cabozantinib was developed by Exelixis, Inc., USA, and is marketed globally as Cabometyx (tablets) and Cometriq (capsules) by Exelixis and its partners; Cabozanix is the branded generic film-coated tablet formulation by Beacon Pharmaceuticals PLC, Bangladesh)
Drug Class Multi-Kinase Inhibitor (VEGFR-1/2/3, MET, AXL, RET, KIT, TRKB, FLT-3, TIE-2); Broad-Spectrum Oral Antiangiogenic and Anti-Invasive Film-Coated Tablet; MET/AXL/VEGFR Resistance-Overcoming Kinase Inhibitor; RET Proto-Oncogene Kinase Inhibitor; First-Line Advanced RCC Immunotherapy Combination Partner (Nivolumab + Cabozantinib, CheckMate 9ER Standard of Care); Second-Line Advanced HCC Monotherapy Agent (Post-Sorafenib, CELESTIAL); Previously Treated DTC and NET Multi-Kinase Inhibitor (Tablet Formulation); Oral VEGFR-MET-AXL Multi-Pathway Resistance-Overcoming TKI for Advanced Solid Tumors; Beacon Pharmaceuticals Bangladesh Oncology Agent
Formulation Film-coated tablet for oral administration take on an empty stomach (at least 1 hour before or at least 2 hours after eating) with a glass of water; swallow tablets whole do not crush, split, or chew; do not take with grapefruit or grapefruit juice, which significantly increases cabozantinib plasma exposure via CYP3A4/5 inhibition and may intensify adverse reactions; take at approximately the same time each day; cabozantinib is administered on a continuous once-daily schedule without scheduled treatment breaks until disease progression or unacceptable toxicity; if a dose is missed and the next scheduled dose is more than 12 hours away, take the missed dose as soon as remembered; if the next dose is due within 12 hours, skip the missed dose and resume at the next scheduled time; do not take a double dose to make up for a missed dose; if vomiting occurs after taking a dose, do not take an additional dose resume at the next regularly scheduled time; store at room temperature as directed per product labeling; avoid concomitant use of strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin, ritonavir, voriconazole, telithromycin, grapefruit juice) if a strong CYP3A4 inhibitor must be used, reduce the cabozantinib daily dose by 20 mg; avoid strong CYP3A4 inducers (rifampin, dexamethasone, phenytoin, carbamazepine, rifabutin, rifapentine, phenobarbital, St. John’s Wort) if a strong CYP3A4 inducer must be used, increase the cabozantinib dose by 20 mg if tolerated (maximum dose 80 mg); hepatic impairment: reduce dose for mild (Child-Pugh A) or moderate (Child-Pugh B) hepatic impairment; cabozantinib is not recommended in severe hepatic impairment (Child-Pugh C); renal impairment: no dose adjustment required based on renal function; the film-coated tablet formulation provides physical tablet integrity enabling ease of handling and swallowing compared to capsule formulations
Available Strengths 20 mg and 60 mg film-coated tablets the dual-strength availability of Cabozanix enables the full clinically recommended dosing range, dose reductions, and all standard indication-specific dose levels from two tablet sizes: Standard monotherapy dose (RCC, HCC, DTC, NET): 60 mg once daily = one 60 mg tablet per day the most convenient single-tablet-per-day regimen; Nivolumab-combination first-line RCC dose: 40 mg once daily = two 20 mg tablets per day; First dose reduction from 60 mg: 40 mg once daily = two 20 mg tablets per day; Second dose reduction: 20 mg once daily = one 20 mg tablet per day; First dose reduction from 40 mg (combination regimen): 20 mg once daily = one 20 mg tablet per day; the 60 mg tablet provides the convenient one-tablet standard monotherapy dose, eliminating the need to combine multiple tablets at the most commonly prescribed dose; the 20 mg tablet is clinically essential for the 40 mg combination-therapy dose, all dose reduction levels in both monotherapy and combination settings, and for weight-based pediatric dosing in patients aged ≥12 years; pediatric dosing (DTC and NET, age ≥12 years): 60 mg once daily for weight ≥40 kg (one 60 mg tablet); 40 mg once daily for weight <40 kg (two 20 mg tablets); no body-weight-based dose adjustment is required for adult patients cabozantinib is administered as a fixed daily dose in adults regardless of body weight or body surface area
Available Pack Size 30 tablets per pot (60 mg) and 90 tablets per pot (20 mg) at the standard monotherapy dose of 60 mg once daily (one 60 mg tablet per day), one pot of Cabozanix 60 MG (30 tablets) provides a precise 30-day supply a one-to-one pot-to-cycle alignment that streamlines monthly procurement with zero partial-pot waste; at the nivolumab-combination dose of 40 mg once daily (two 20 mg tablets per day), one pot of Cabozanix 20 MG (90 tablets) provides a 45-day supply; at the 20 mg once-daily dose reduction level (one 20 mg tablet per day), one pot of Cabozanix 20 MG (90 tablets) provides a 90-day supply; at 60 mg using 20 mg tablets (three 20 mg tablets per day for patients where only 20 mg tablets are dispensed), one pot of Cabozanix 20 MG (90 tablets) provides a 30-day supply; the 30-tablet pot of Cabozanix 60 MG is the standard monthly procurement unit for HCC, RCC, DTC, and NET patients receiving 60 mg once-daily monotherapy; hospital oncology programs and patient access programs benefit from the per-indication alignment of the 30-tablet 60 mg pot (one pot = one monthly cycle) for streamlined prescription, dispensing, and adherence monitoring; contact Mediaid Pharmacy for indication-specific procurement guidance, combined 20 mg + 60 mg pack sourcing, and current stock availability for Cabozanix 20 MG and Cabozanix 60 MG
Dosing Schedule Advanced Renal Cell Carcinoma (RCC) First-Line Combination with Nivolumab (CheckMate 9ER Regimen): Cabozantinib 40 mg orally once daily (two 20 mg tablets) on an empty stomach in combination with nivolumab 240 mg intravenously every 2 weeks or 480 mg every 4 weeks; administer until disease progression or unacceptable toxicity; manage immune-mediated adverse reactions from nivolumab per nivolumab prescribing information; this regimen is based on CheckMate 9ER and is the most prescribed TKI-IO combination for first-line advanced RCC as of 2025 (IQVIA BrandImpact data).

Advanced Renal Cell Carcinoma (RCC) Monotherapy (Any Line): Cabozantinib 60 mg orally once daily (one 60 mg tablet) on an empty stomach; administer continuously until disease progression or unacceptable toxicity.

Previously Treated Advanced Hepatocellular Carcinoma (HCC Post-Sorafenib): Cabozantinib 60 mg orally once daily (one 60 mg tablet) on an empty stomach in patients with Child-Pugh Class A hepatic function; reduce dose to 40 mg once daily (two 20 mg tablets) for moderate hepatic impairment (Child-Pugh B); administer continuously until disease progression or unacceptable toxicity; approved based on the CELESTIAL trial; cabozantinib is approved for both second-line (post-sorafenib only) and third-line (post-sorafenib plus one additional therapy) HCC settings the only approved post-sorafenib agent validated across both settings.

Previously Treated Differentiated Thyroid Cancer (DTC): Cabozantinib 60 mg orally once daily (one 60 mg tablet) on an empty stomach in adult and pediatric patients aged ≥12 years with locally advanced or metastatic DTC that has progressed following prior VEGFR-targeted therapy and who are RAI-refractory or ineligible; pediatric ≥12 years and weight ≥40 kg: 60 mg once daily; pediatric ≥12 years and weight <40 kg: 40 mg once daily (two 20 mg tablets); FDA approved September 17, 2021.

Previously Treated Neuroendocrine Tumors (NET March 2025 FDA Approval): Cabozantinib 60 mg orally once daily (one 60 mg tablet) on an empty stomach in adult and pediatric patients aged ≥12 years with previously treated pancreatic and extra-pancreatic NET; pediatric weight-based dosing: same as DTC above; FDA approved March 2025 the most recently added indication for the cabozantinib tablet formulation.

Dose Reduction Schedule (All Tablet-Formulation Indications): From 60 mg: First reduction to 40 mg (two 20 mg tablets); Second reduction to 20 mg (one 20 mg tablet); From 40 mg (combination): First reduction to 20 mg (one 20 mg tablet); Permanently discontinue if the patient cannot tolerate 20 mg once daily.

Mandatory Safety Monitoring Before Initiating Cabozanix: Assess and optimize blood pressure control; evaluate hepatic function (ALT, AST, bilirubin, alkaline phosphatase); measure serum calcium; review planned surgical procedures (withhold at least 3 weeks before elective surgery); perform preventive dental evaluation to minimize osteonecrosis of jaw risk (avoid invasive dental procedures during treatment); assess for thromboembolic and hemorrhagic risk factors; perform serum or urine pregnancy test in all females of reproductive potential before initiating therapy.

Manufacturer Beacon Pharmaceuticals PLC, Bangladesh a leading Bangladeshi pharmaceutical manufacturer producing high-quality oncology generics including oral targeted therapy small molecules, immunotherapy adjuncts, cytotoxic agents, and specialty precision oncology products for domestic and international patient access, hospital procurement, and healthcare provider supply programs worldwide
Country of Origin Bangladesh
Categories Kidney Cancer Medicines | Liver Cancer Medicines | Oncology Medicines | Thyroid Cancer Medicines | Beacon Pharmaceuticals Medicines

Four Clinical and Practical Reasons to Source Cabozanix 20 MG & 60 MG (Cabozantinib) Through Mediaid Pharmacy

First, the film-coated tablet formulation of Cabozanix delivers cabozantinib’s established multi-kinase VEGFR + MET + AXL + RET inhibition profile through a convenient once-daily single-tablet regimen at the 60 mg monotherapy dose, optimizing patient adherence and oral treatment compliance across all four approved tablet-formulation indications spanning kidney cancer, liver cancer, differentiated thyroid cancer, and neuroendocrine tumors. Clear cell renal cell carcinoma (ccRCC) is uniquely dependent on VEGF pathway activation due to VHL tumor suppressor loss driving HIF-1α/HIF-2α constitutive stabilization and downstream VEGF-A, VEGF-C, and PDGF-B overexpression; hepatocellular carcinoma is a highly vascularized malignancy with significant VEGF and HGF/MET pathway dependence; differentiated thyroid cancer accumulates VEGFR-driven angiogenesis dependence particularly following RAI failure; and neuroendocrine tumors express VEGF, VEGFR, MET, and AXL across pancreatic and extra-pancreatic tumor sites cabozantinib’s simultaneous inhibition of all these target pathways in a single once-daily film-coated tablet delivers multi-indication clinical activity from one drug, one dose, one tablet; at the standard 60 mg dose, Cabozanix requires only a single 60 mg tablet per day unlike multi-tablet dosing regimens common with 20 mg or 40 mg tablet-only products minimizing daily pill burden and simplifying twice-daily or multi-tablet regimen complexity for patients managing chronic oral oncology therapy.

Second, the pivotal CheckMate 9ER trial data establishing nivolumab plus cabozantinib as the most prescribed first-line TKI-IO combination for advanced RCC represent the highest-evidence confirmation of cabozantinib’s clinical activity and tolerability in a first-line setting, with 4-year minimum follow-up sustained benefit across all IMDC risk categories and tumor histological subgroups. CheckMate 9ER (NCT03141177; Phase III; n=651; nivolumab 240 mg every 2 weeks + cabozantinib 40 mg once daily vs. sunitinib 50 mg once daily; primary endpoint PFS by BICR; 4-year minimum follow-up median 55.6 months) demonstrated: Confirmed ORR 55.7% (cabozantinib + nivolumab) versus 27.7% (sunitinib) more than doubling objective response rate; median PFS doubled over sunitinib (HR 0.51; 95% CI 0.41–0.64; p<0.0001); OS HR 0.70 (95% CI 0.55–0.90) statistically significant overall survival benefit maintained at 4-year follow-up; efficacy benefits preserved across all IMDC risk groups (favorable, intermediate, and poor risk) and sarcomatoid histology subgroups; nivolumab plus cabozantinib is listed as a Category 1 preferred first-line regimen in NCCN Kidney Cancer Guidelines and is described by IQVIA BrandImpact data as the most widely prescribed TKI-IO combination for first-line advanced RCC as of September 2025; the 40 mg combination dose is precisely delivered by two 20 mg Cabozanix tablets, which is the standard cabozantinib tablet dose in this regimen.

Third, the CELESTIAL trial data validating cabozantinib in previously sorafenib-treated HCC and the March 2025 NET approval confirm cabozantinib’s expansion as the only oral multi-kinase inhibitor with simultaneous regulatory approvals in four distinct solid tumor types within the same tablet formulation kidney cancer, liver cancer, differentiated thyroid cancer, and neuroendocrine tumors. CELESTIAL (NCT01908426; Phase III; n=707; cabozantinib 60 mg QD vs. placebo; 2:1 randomization; primary endpoint OS) demonstrated: Median OS 10.2 months versus 8.0 months (HR 0.76; 95% CI 0.63–0.92; p=0.0049); median PFS 5.2 months versus 1.9 months (HR 0.44; p<0.0001); ORR 4% versus 0.4% (p=0.0086); disease control rate 64% versus 33%; CELESTIAL enrolled both second-line (post-sorafenib only) and third-line patients, confirming cabozantinib’s clinical benefit irrespective of prior therapy count the only Phase III HCC trial to include third-line patients with positive results; the March 2025 FDA approval of cabozantinib for previously treated pancreatic and extra-pancreatic neuroendocrine tumors adds the fourth approved indication in the film-coated tablet formulation, making Cabozanix 20 MG & 60 MG the only Beacon Pharmaceuticals-manufactured cabozantinib tablet product covering kidney cancer, liver cancer, thyroid cancer, and neuroendocrine tumor indications from a single film-coated tablet product line.

Fourth, the 30-tablet pot of Cabozanix 60 MG creates a one-to-one monthly treatment cycle alignment one pot per patient per 30-day prescription cycle at the standard monotherapy dose while the 90-tablet pot of Cabozanix 20 MG provides the full 45-day supply at the 40 mg nivolumab-combination dose from a single procurement unit, eliminating the packaging management complexity common with other tablet strength configurations. At the 60 mg once-daily monotherapy dose (one 60 mg tablet per day), one pot of Cabozanix 60 MG (30 tablets) = exactly one 30-day monthly treatment cycle a supply-cycle alignment that eliminates partial pot waste and simplifies hospital pharmacy dispensing, monthly prescription management, insurance documentation, and patient refill planning; at the 40 mg once-daily nivolumab-combination dose (two 20 mg tablets per day), one pot of Cabozanix 20 MG (90 tablets) provides 45 days of supply covering a full nivolumab q3-week (or q4-week 480 mg) cycle window and reducing the monthly procurement frequency for the cabozantinib component of the regimen; Mediaid Pharmacy maintains stock of both Cabozanix 20 MG and Cabozanix 60 MG with reliable international supply continuity to prevent treatment interruptions across all four indicated tumor types.

To source Cabozanix 20 MG & 60 MG Cabozantinib and explore the complete portfolio of kidney cancer, liver cancer, thyroid cancer, and oncology medicines manufactured by Beacon Pharmaceuticals, visit the Mediaid Pharmacy kidney cancer medicines portfolio, the liver cancer medicines collection, the thyroid cancer medicines range, the oncology medicines collection, and the Beacon Pharmaceuticals medicines range, and contact the team for a personalized quotation and international shipping confirmation.

Frequently Asked Questions About Cabozanix 20 MG & 60 MG (Cabozantinib)

What is Cabozanix 20 MG & 60 MG (Cabozantinib) used for?

Cabozanix (Cabozantinib) film-coated tablet is an oral multi-kinase inhibitor with four approved oncology indications in the film-coated tablet formulation spanning kidney cancer, liver cancer, thyroid cancer, and neuroendocrine tumors. Indication 1 Advanced RCC (Any Line, Monotherapy): Cabozantinib 60 mg once daily for adult patients with advanced renal cell carcinoma; approved April 25, 2016. Indication 2 First-Line Advanced RCC with Nivolumab (CheckMate 9ER): Cabozantinib 40 mg once daily (two 20 mg tablets) plus nivolumab for previously untreated advanced RCC; CheckMate 9ER demonstrated ORR 55.7%, PFS doubled vs. sunitinib (HR 0.51), and significant OS benefit (HR 0.70); FDA approved January 22, 2021; most prescribed TKI-IO first-line RCC regimen as of 2025. Indication 3 Previously Treated Advanced HCC (CELESTIAL): Cabozantinib 60 mg once daily (one 60 mg tablet) for adult patients with advanced HCC previously treated with sorafenib (Child-Pugh Class A); CELESTIAL: median OS 10.2 vs. 8.0 months (HR 0.76; p=0.0049); FDA approved January 14, 2019. Indication 4 Previously Treated DTC and NET: Cabozantinib 60 mg once daily for DTC progressed on prior VEGFR therapy that is RAI-refractory or ineligible (FDA approved September 17, 2021) and for previously treated pancreatic and extra-pancreatic NET (FDA approved March 2025); pediatric use approved in DTC and NET for patients aged ≥12 years. Cabozanix 20 MG & 60 MG (Cabozantinib) is available through Mediaid Pharmacy with worldwide shipping to kidney cancer programs, liver cancer treatment centers, and thyroid cancer programs globally.

What is the difference between Cabozanix film-coated tablet and cabozantinib capsule formulations?

Cabozanix (film-coated tablet, 20 mg and 60 mg) is the tablet formulation of cabozantinib, equivalent to the Cabometyx® tablet reference product it covers four indications: advanced RCC (monotherapy and nivolumab combination), previously treated advanced HCC, previously treated DTC, and previously treated NET. The cabozantinib capsule formulation (20 mg and 80 mg capsules equivalent to Cometriq®) is specifically approved for progressive metastatic medullary thyroid cancer (MTC) at a dose of 140 mg once daily. These two formulations are NOT interchangeable they differ in salt form, pharmacokinetic behavior, approved indications, and dose strengths; the reference label states explicitly that Cabometyx tablets must not be substituted for Cometriq capsules and vice versa. Key Practical Differences Tablet vs. Capsule Formulation: Cabozanix (tablet) covers RCC, HCC, DTC, and NET at 60 mg once daily (or 40 mg for nivolumab combination); standard monotherapy dose = one 60 mg tablet (simple single-tablet regimen); dose reductions in 20 mg steps (40 mg → 20 mg). Cabozantinib capsule formulation covers medullary thyroid cancer (MTC) at 140 mg once daily (one 80 mg + three 20 mg capsules); dose reductions in 20 mg steps (100 mg → 60 mg → 40 mg). Clinical Selection Guidance: For kidney cancer, liver cancer, differentiated thyroid cancer (post-VEGFR), and NET the film-coated tablet formulation (Cabozanix) is the appropriate reference; for medullary thyroid cancer (MTC) driven by RET mutations the capsule formulation is specifically indicated. Contact your treating oncologist to confirm which formulation is appropriate for your indication. Mediaid Pharmacy offers both formulations; visit the thyroid cancer medicines collection and the Beacon Pharmaceuticals medicines range for the complete cabozantinib portfolio.

What are the side effects of Cabozanix (Cabozantinib) film-coated tablets?

The most clinically significant adverse reactions of Cabozanix (Cabozantinib) are hemorrhage (including fatal events), gastrointestinal perforations and fistulas, arterial and venous thrombotic events, hypertension, diarrhea, palmar-plantar erythrodysesthesia (PPE/hand-foot syndrome), hepatotoxicity, osteonecrosis of the jaw, Reversible Posterior Leukoencephalopathy Syndrome (RPLS), thyroid dysfunction, hypocalcemia, wound healing complications, and embryo-fetal toxicity. Hemorrhage (Most Serious Risk Do Not Administer to Active Bleeders): Severe and fatal hemorrhagic events have occurred; Grade 3–5 hemorrhagic events incidence was 5% in RCC and HCC clinical studies; permanently discontinue for Grade 3 or 4 hemorrhage; patients on concomitant anticoagulants or antiplatelet therapy require especially close hemorrhagic event monitoring. Diarrhea and PPE (Primary Dose-Limiting Toxicities): Diarrhea: occurred in up to 62% of cabozantinib-treated patients in CELESTIAL (10% Grade 3); PPE: 45% of CELESTIAL patients (13–17% Grade 3); diarrhea and PPE are the leading causes of dose withhold (37% and 25% respectively) and dose reduction (10% and 22%) in clinical practice; preventive skin care, loperamide-based diarrhea management, padded footwear, and prompt dose modification significantly reduce PPE and diarrhea impact on treatment continuity. Hypertension: Grade 3 hypertension in 16% of CELESTIAL patients; blood pressure must be controlled before initiating cabozantinib; treat antihypertensively throughout; permanently discontinue for uncontrolled severe hypertension. Hepatotoxicity: Liver enzyme elevations are common; monitor ALT, AST, and bilirubin before initiation and periodically; withhold or discontinue for severe hepatotoxicity. Osteonecrosis of the Jaw (ONJ): ONJ has been reported with cabozantinib; preventive dental evaluation before initiating is mandatory; avoid invasive dental procedures during treatment; withhold cabozantinib at least 3 weeks before scheduled oral surgery. Hypocalcemia: Monitor serum calcium before initiating and during treatment; withhold cabozantinib for hypocalcemia and resume at a reduced dose when corrected; hypocalcemia risk is higher in patients with thyroid cancer history due to prior thyroid/parathyroid surgical history. Most Common (≥20%) Adverse Reactions Monotherapy: Diarrhea, fatigue, PPE, decreased appetite, hypertension, nausea, vomiting, weight decreased, and constipation. Most Common (≥20%) Adverse Reactions Nivolumab Combination in RCC: Diarrhea, fatigue, hepatotoxicity, PPE, stomatitis, rash, hypertension, hypothyroidism, musculoskeletal pain, decreased appetite, nausea, dysgeusia, abdominal pain, cough, and upper respiratory tract infection. All patients initiating Cabozanix (Cabozantinib) must have baseline assessments of blood pressure, hepatic function, serum calcium, dental health, and reproductive status documented, with treatment initiated under the supervision of a qualified oncologist experienced in managing VEGFR-MET multi-kinase inhibitor toxicities.

How effective is Cabozanix (Cabozantinib) for kidney cancer, liver cancer, and thyroid cancer?

Cabozantinib film-coated tablets have demonstrated statistically significant, clinically meaningful, and durably sustained efficacy across its four approved indications. CheckMate 9ER First-Line Advanced RCC, Nivolumab Combination (NCT03141177; Phase III; n=651; 4-year follow-up at median 55.6 months; nivolumab 240 mg q2w + cabozantinib 40 mg QD vs. sunitinib 50 mg QD): ORR 55.7% vs. 27.7% (more than doubling); median PFS doubled (HR 0.51; 95% CI 0.41–0.64; p<0.0001); OS HR 0.70 (95% CI 0.55–0.90) statistically significant 30% reduction in death risk; benefits consistent across all IMDC risk groups; most prescribed TKI-IO combination for first-line advanced RCC as of 2025. CELESTIAL Previously Treated Advanced HCC (NCT01908426; Phase III; n=707; cabozantinib 60 mg QD vs. placebo; 2:1; primary endpoint OS): Median OS 10.2 vs. 8.0 months (HR 0.76; 95% CI 0.63–0.92; p=0.0049); median PFS 5.2 vs. 1.9 months (HR 0.44; p<0.0001); ORR 4% vs. 0.4% (p=0.0086); disease control rate 64% vs. 33%; efficacy confirmed irrespective of prior therapy line, AFP level, age, and HCC etiology. COSMIC-311 Previously Treated DTC (NCT03690388; Phase III; n=187; cabozantinib 60 mg QD vs. placebo; primary endpoints PFS and ORR at week 12): Statistically significant PFS improvement (HR 0.22; 95% CI 0.15–0.32; p<0.0001) the COSMIC-311 PFS hazard ratio of 0.22 represents one of the most dramatic PFS improvements reported for any approved oncology agent in its setting; establishing cabozantinib as a standard second-line agent following progression on prior lenvatinib or sorafenib in RAI-refractory DTC. Cabozanix 20 MG & 60 MG (Cabozantinib) is available through Mediaid Pharmacy; visit the kidney cancer medicines collection and the liver cancer medicines collection for the full oncology product portfolio.

What is the recommended dose of Cabozanix (Cabozantinib) and how should it be taken?

The standard recommended dose of Cabozanix (Cabozantinib) depends on the indication and whether it is used as monotherapy or in combination. Standard Monotherapy Dose (RCC Monotherapy, HCC, DTC, NET): 60 mg orally once daily taken as one 60 mg film-coated tablet per day, on an empty stomach (at least 1 hour before or at least 2 hours after eating); do not take with grapefruit or grapefruit juice; swallow tablets whole without crushing, splitting, or chewing. Nivolumab Combination Dose (First-Line Advanced RCC): 40 mg orally once daily taken as two 20 mg film-coated tablets per day, on an empty stomach; nivolumab is administered as an intravenous infusion (240 mg every 2 weeks or 480 mg every 4 weeks); manage immune-mediated adverse reactions from nivolumab per the nivolumab prescribing information separately from cabozantinib dose modification. Dose Modifications: If cabozantinib must be taken with a strong CYP3A4 inhibitor (e.g., ketoconazole, clarithromycin), reduce the daily cabozantinib dose by 20 mg; if a strong CYP3A4 inducer must be used (e.g., rifampin), increase the daily dose by 20 mg if tolerated (maximum 80 mg daily); for adverse reactions, reduce from 60 mg to 40 mg (two 20 mg tablets), then to 20 mg (one 20 mg tablet); for mild hepatic impairment (Child-Pugh A): reduce dose; for moderate hepatic impairment (Child-Pugh B): reduce dose; for severe hepatic impairment (Child-Pugh C): not recommended. Missed Dose: If the next dose is more than 12 hours away, take the missed dose immediately; if within 12 hours, skip and resume at the next scheduled time never double-dose. Cabozantinib does not require body-weight-based dose calculation in adult patients; pediatric patients aged ≥12 years require weight-based dosing (60 mg for ≥40 kg; 40 mg for <40 kg). Always take Cabozanix under the supervision of a qualified oncologist and follow the treating physician’s dose instructions precisely.

Is Cabozanix (Cabozantinib) safe during pregnancy or while breastfeeding?

Cabozanix (Cabozantinib) can cause fetal harm when administered during pregnancy and must not be used during pregnancy. VEGFR, MET, AXL, and RET kinase signaling are all required for normal embryonic vascular development, placentation, and organ morphogenesis; cabozantinib’s simultaneous inhibition of these four essential developmental signaling pathways is expected to cause significant fetal toxicity; nonclinical animal reproductive toxicology studies confirmed embryo-fetal toxicity at cabozantinib exposures in animals, including decreased fetal weight, increased skeletal abnormalities, and increased post-implantation loss, supporting the clinical expectation of fetal harm. Contraception requirement: Females of reproductive potential must use effective contraception during cabozantinib treatment and for 4 months after the last dose; males with female partners of reproductive potential must use condoms during treatment and for 4 months after the last dose; the 4-month post-treatment contraception requirement for both sexes reflects cabozantinib’s extended tissue distribution and effective half-life and is longer than the contraception requirement for most other oral TKIs (e.g., 1 week post-treatment for axitinib); verify pregnancy status with a serum or urine pregnancy test before initiating Cabozanix in all females of reproductive potential; notify the treating oncologist immediately if pregnancy occurs or is suspected during treatment. Breastfeeding: No data exist on the presence of cabozantinib or its metabolites in human breast milk, effects on breastfed infants, or effects on milk production; because of the potential for serious adverse reactions from cabozantinib in breastfed infants, breastfeeding is not recommended during cabozantinib treatment and for 4 months after the last dose. Male Fertility: Cabozantinib may adversely affect male fertility based on nonclinical findings; discuss fertility preservation options with the treating oncologist before initiating Cabozanix in male patients of reproductive potential. All aspects of reproductive planning should be discussed with the treating oncologist before starting Cabozanix therapy.

Can I order Cabozanix 20 MG & 60 MG (Cabozantinib) online with worldwide shipping?

Yes. Mediaid Pharmacy supplies Cabozanix 20 MG & 60 MG (Cabozantinib) film-coated tablets, available in 90 tablets per pot (20 mg) and 30 tablets per pot (60 mg), manufactured by Beacon Pharmaceuticals PLC, Bangladesh, to patients, advanced RCC treatment programs, HCC centers, differentiated thyroid cancer clinics, neuroendocrine tumor programs, oncology departments, hospital pharmacies, outpatient oncology clinics, patient access programs, and healthcare providers globally. As a film-coated tablet stored at room temperature, Cabozanix does not require cold-chain refrigerated shipping, allowing straightforward international logistics with standard secure pharmaceutical packaging appropriate for the destination country’s regulatory and transit requirements. Contact Mediaid Pharmacy via WhatsApp, phone, or email at +8801773428128, or email info@mediaidpharmacy.com for pricing, current stock availability for both 20 mg and 60 mg tablet strengths, combined-strength procurement options, international shipping lead times, and delivery details for your country. Prescription documentation is required for cabozantinib dispensing in accordance with applicable regulatory requirements in the destination country. For the complete portfolio of Beacon Pharmaceuticals medicines, kidney cancer medicines, liver cancer medicines, thyroid cancer medicines, and oncology medicines available with worldwide shipping, visit the respective collection pages on the Mediaid Pharmacy website.

Order Cabozanix 20 MG & 60 MG (Cabozantinib) with Worldwide Shipping

Phone / WhatsApp: +8801773428128  |  Email: info@mediaidpharmacy.com

Message on WhatsApp

 

Reviews

There are no reviews yet.

Be the first to review “Cabozanix 20 MG & 60 MG (Cabozantinib)”

Your email address will not be published. Required fields are marked *